Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Sleep and awakening disorders in Parkinson’s disease: comprehensive approach to therapy

https://doi.org/10.14412/2074-2711-2012-360

Full Text:

Abstract

The paper presents the specific features of the clinical presentation and pathophysiology of sleep and awakening disorders in patients with Parkinson’s disease (PD). It covers the current views of the role of chronobiological mechanisms in the regulation of sleep and awakening in PD. Major approaches to therapy for insomnia, para-, and hypersomnia in these patients are discussed. Data on the efficacy of melatonin in sleep and awakening disorders are given.

About the Author

Marina Romanovna Nodel

Department of Nervous Diseases, Faculty of Therapeutics


References

1. <div><p>Нодель М.Р., Яхно Н.Н. Нервно-психические нарушения болезни Паркинсона. Неврол нейропсихиатр психосом 2009;2:3-8.</p><p>Нодель М.Р., Русакова И.М., Яхно Н.Н. Клиническая оценка нарушений сна и бодрствования при болезни Паркинсона. Неврол журн 2010;2:19-25.</p><p>Shulman L.M., Taback R.L., Rabinstein A.A. et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Dis 2002;8(3):193—7.</p><p>Gallagher D.A., Lees A.J., Shrag A. What are the most important non-motor symptoms in patients with Parkinsons disease and are we missing them? Mov Dis 2011;25(15):2493—500.</p><p>Tandberg E., Larsen J.P., Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Dis 1999;14(6):922-6.</p><p>Rye D.B., Bliwise D.L. Movement disorders specific to sleep and nocturnal manifestations of movement disorders. In: R.L. Watts, W.C. Koller (Ed.) Movement disorders: neurologic principles and practice. New York: McGraw-Hill 2004;855-90.</p><p>Comella C. Sleep disorders in Parkinsons disease: an overview. Mov Dis (Suppl.17) 2007;22:367-73.</p><p>Larsen J.P. Sleep disorders in Parkinsons disease. Adv Neurol 2003;91:329-4.</p><p>Factor S.A., McAlarney T., Sanchez-Ramos J.R. et al. Sleep disorders and sleep effect in Parkinson’s disease. Mov Dis 1990;5:280-5.</p><p>Vendette M., Gagnon J.F., Dеcary A. et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007;69(19):1843-9.</p><p>Arnulf I., Konofal E., Merino-Andreu M. et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002;58(7):1019—24.</p><p>Brodsky M.A., Godbold J., Roth T. et al. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003;18(6):668—72.</p><p>Shpirer I., Miniovitz A., Klein C. et. al. Excessive Daytime Sleepiness in Patients With Parkinson’s disease: A Polysomnography Study. Mov Dis 2006;21(9):1432-8.</p><p>Paus S., Brecht H.M., Köster J. et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Dis 2003;18(6):659—67.</p><p>Gjerstad M.D., Aarsland D., Larsen J.P. Development of daytime somnolence over time in Parkinson's disease. Neurology 2002;58(10):1544-6.</p><p>Boddy F., Rowan E.N., Lett D. et al. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy body and Alzheimers disease. Int J Geriatr Psychiatr 2007;22:529-35.</p><p>Saper C.B., Lu J., Chou T.C. et al. The hypothalamic integrator for circadian rhythms. Trend Neurosci 2005;28:152-7.</p><p>Srinivasan V., Cardinali D.P., Srinivasan U.S. et al. Therapeutic potential of melatonin and its analogs in Parkinsons disease: focus on sleep and neuroprotection. Ther Аdv Neurol Dis 2011;4(5):297—317.</p><p>Braak H., Del Tredici K., Rub U. et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurol Aging 2003;24:197-210.</p><p>Ray D.B., Jankovic J. Emerging views of dopamine in modulating sleep / wake state from an unlikely source: PD. Neurology 2002;58:341-6.</p><p>Hilker R., Razai N., Ghaemi M. et al. F fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinsons disease. Clin Neurol 2003;105:262-9.</p><p>Beine B. Neurophysiologic basis of sleep and walkefulness. In.: N. Butkov, T. Lee-Choing. (Eds.). Fundamentals of sleep technology. LWW Philadelphia, 2007;11—7.</p><p>Bordet R., Devos D., Brique S. et al. Study of circadian melatonine secretion pattern at different stages of Parkinsons disease. Clin Neuropharmacol 2003;26(2):65-72.</p><p>Fertl E., Auff E., Doppelbauer A. et al. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect 1993;5(3):227-34.</p><p>Adi N., Mash D.C., Ali E. et al. Melatonin MT1 and MT2 receptors expression in Parkinsons disease. Med Sci Monit 2010;BR61—BR67.</p><p>Day J., Damsma G., Fibiger H.C. Cholinergic activity in the rat hippocampus, cortex and striatum correlates with locomotor activity. Pharmacol Biochem Behav 1991;38:723—9.</p><p>Cai Y., Liu S., Sothern R.B. et al. Expression of clock genes Per1 and Bmall 1 in total leukocytes in health and Parkinsons disease. Eur J Neurol 2010;17:550—4.</p><p>Van Hilten B., Hoff J.I., Middelkoop H.A. et al. Sleep disruption in Parkinsons disease. Assessment by continuous activity monitoring. Arch Neurol 1994;51:922—8.</p><p>Van Hilten B., Hoff J.I., Middelkoop H.A. et al. Sleep disruption in Parkinsons disease. Assessment by continuous activity monitoring. Arch Neurol 1994;51:922—8.</p><p>The UK Madopar CR Study Group. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early morning disability in of Parkinsons disease. Clin Neuropharmacol 1989;12(6):498—505.</p><p>Leeman A.L., O Neill C.J., Nicholson P.W. et al. Parkinsons disease in the elderly : response to an optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987;24(6):637—43.</p><p>Яхно Н.Н., Нодель М.Р., Федорова Н.В. и др. Эффективность и переносимость препарата Сталево при болезни Паркинсона. Неврол журн 2007;6:48-52.</p><p>Poewe W.H., Rascol O., Quinn N. et al. On behalf of the SP515 Investigators. Efficaсy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy , randomized controlled trial. Lancet Neurol 2007;6:513-20.</p><p>Pahwa R., Stacy M.A., Factor S.A. et al. Ropinirole 24-hour prolonged release: a randomized, controlled study in advanced Parkinsons disease. Neurology 2007;68:1108-6.</p><p>Нодель М.Р., Яхно Н.Н. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журн неврол и психиатр 2008;108(5):32—8.</p><p>Blackett H., Walker R., Wood B. Urinary dysfunction in Parkinsons disease: a review. Park Relat Dis 2009;15:81-7.</p><p>Zesiewich T.A., Sullivan K.L., Arnulf I. et al. Practice parameter: treatment of nonmotor symptoms of Parkinsons disease. Neurology 2010;74:924-31.</p><p>Brzezinski A., Vangel M.G., Wurtmanc R.J. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50.</p><p>Haimov N., Lavie P., Laudon M. et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18(7):598-603.</p><p>Kunz D., Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Dis 1999;14:507-11.</p><p>Dowling G., Mastick J., Colling E. et al. Melatonin for sleep disturbances in in PD. Sleep Med 2005;6:459-66.</p><p>Medeiros C.A., Carvalhedo de Bruin P.F., Lopes L.A. et al. Effect of exogenous melatonin on sleep and motor dysfunction in PD. A randomized, double blind, placebo controlled study. J Neurol 2007;254(4):459-69.</p><p>Литвиненко И.В., Красаков И.В., Тихомирова О.В. Нарушения сна при болезни Паркинсона: патофизиологические механизмы, клинические варианты и направления коррекции. Рук-во для врачей. По материалам II национального конгресса по болезни Паркинсона и расстройствам движения. Под ред. С.Н. Иллариошкина, О.С. Левина. М.,2011.</p></div><br />


For citation:


Nodel M.R. Sleep and awakening disorders in Parkinson’s disease: comprehensive approach to therapy. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(1):43-48. (In Russ.) https://doi.org/10.14412/2074-2711-2012-360

Views: 441


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)